NCT05554367 2026-03-18
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT05195632 2026-01-07
OCEANII
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04061980 2025-11-19
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Providence Health & Services
Phase 2 Active not recruiting
NCT04439344 2025-11-19
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04526782 2025-11-18
ENCO-BRAF
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Active not recruiting
NCT05170334 2025-10-01
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03235245 2025-08-01
EBIN
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT04074096 2024-06-03
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting